These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 37560958

  • 1. [Clinically amyopathic dermatomyositis : a rare entity associated with acute and severe interstitial lung disease].
    Debrus C, Calmes D, Von Frenckell C, Duysinx B, Cataldo D, Corhay JL, Louis R, Guiot J.
    Rev Med Liege; 2023 Jul; 78(7-8):441-447. PubMed ID: 37560958
    [Abstract] [Full Text] [Related]

  • 2. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 3. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H, Fumiaki A, Nozomi A, Toshitaka M, Masayoshi Y, Chikako K, Yoshinao M, Tatsuo S, Masahiko K.
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [Abstract] [Full Text] [Related]

  • 4. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q, Pan W, Zhang D, Hou Y, Wang Z.
    Front Immunol; 2023 May; 14():1237209. PubMed ID: 38098481
    [Abstract] [Full Text] [Related]

  • 5. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, Lu LJ, Dai M, Lv X, Bao C.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3343-3351. PubMed ID: 33331866
    [Abstract] [Full Text] [Related]

  • 6. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
    Horino T, Inotani S, Nakajima K, Ohnishi H, Komori M, Terada Y.
    Joint Bone Spine; 2022 Nov 01; 89(6):105456. PubMed ID: 36108903
    [No Abstract] [Full Text] [Related]

  • 7. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, Hara A, Kitazaki T, Kakugawa T, Ishimatsu Y, Satoh M, Mukae H.
    Intern Med; 2019 Mar 15; 58(6):837-841. PubMed ID: 30449789
    [Abstract] [Full Text] [Related]

  • 8. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
    Mehta AA, Paul T, Cb M, Haridas N.
    BMJ Case Rep; 2021 Apr 28; 14(4):. PubMed ID: 33910791
    [Abstract] [Full Text] [Related]

  • 9. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y, Fu Q, Wang R, Guo Q, Bao C.
    J Clin Lab Anal; 2019 Oct 28; 33(8):e22978. PubMed ID: 31301087
    [Abstract] [Full Text] [Related]

  • 10. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
    McPherson M, Economidou S, Liampas A, Zis P, Parperis K.
    Semin Arthritis Rheum; 2022 Apr 28; 53():151959. PubMed ID: 35134633
    [Abstract] [Full Text] [Related]

  • 11. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, Sato S.
    Respir Med; 2015 Sep 28; 109(9):1174-80. PubMed ID: 26187000
    [Abstract] [Full Text] [Related]

  • 12. Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.
    Wang W, Sun X, Xu Y, Tan W, Liu Y, Zhou J.
    Immun Inflamm Dis; 2024 Jun 28; 12(6):e1332. PubMed ID: 38934403
    [Abstract] [Full Text] [Related]

  • 13. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study.
    Zhou S, Lai J, Wu C, Liu Y, Liu Y, Zhao J, Xu D, Tian X, Li M, Zhao Y, Wang Y, Wang Q, Zeng X.
    Front Immunol; 2022 Jun 28; 13():928861. PubMed ID: 35983058
    [Abstract] [Full Text] [Related]

  • 14. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug 28; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 15. Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.
    Yamazoe M, Takeda K, Nagano Y, Nagano K, Kato K, Inoue T, Horiuchi K, Kamada K.
    Intern Med; 2024 Sep 15; 63(18):2571-2578. PubMed ID: 38346740
    [Abstract] [Full Text] [Related]

  • 16. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
    Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M.
    Chest; 2013 Dec 15; 144(6):1934-1936. PubMed ID: 24297126
    [Abstract] [Full Text] [Related]

  • 17. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
    Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A.
    Medicine (Baltimore); 2018 Jun 15; 97(26):e11024. PubMed ID: 29952940
    [Abstract] [Full Text] [Related]

  • 18. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M, Asano T, Sato S, Kobayashi H, Watanabe H, Miyata M, Migita K.
    Fukushima J Med Sci; 2018 Jun 15; 64(2):89-94. PubMed ID: 30158335
    [Abstract] [Full Text] [Related]

  • 19. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T, Morimoto K, Sasaki Y, Matsuda S, Yamana K, Yano R, Uchiyama T, Goto H.
    Intern Med; 2018 Feb 01; 57(3):387-391. PubMed ID: 29093381
    [Abstract] [Full Text] [Related]

  • 20. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T.
    Medicina (Kaunas); 2021 Apr 03; 57(4):. PubMed ID: 33916864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.